1
|
Alhujaily M. Glyoxalase System in Breast and Ovarian Cancers: Role of MEK/ERK/SMAD1 Pathway. Biomolecules 2024; 14:584. [PMID: 38785990 PMCID: PMC11117840 DOI: 10.3390/biom14050584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2024] [Revised: 05/03/2024] [Accepted: 05/05/2024] [Indexed: 05/25/2024] Open
Abstract
The glyoxalase system, comprising GLO1 and GLO2 enzymes, is integral in detoxifying methylglyoxal (MGO) generated during glycolysis, with dysregulation implicated in various cancer types. The MEK/ERK/SMAD1 signaling pathway, crucial in cellular processes, influences tumorigenesis, metastasis, and angiogenesis. Altered GLO1 expression in cancer showcases its complex role in cellular adaptation and cancer aggressiveness. GLO2 exhibits context-dependent functions, contributing to both proapoptotic and antiapoptotic effects in different cancer scenarios. Research highlights the interconnected nature of these systems, particularly in ovarian cancer and breast cancer. The glyoxalase system's involvement in drug resistance and its impact on the MEK/ERK/SMAD1 signaling cascade underscore their clinical significance. Furthermore, this review delves into the urgent need for effective biomarkers, exemplified in ovarian cancer, where the RAGE-ligand pathway emerges as a potential diagnostic tool. While therapeutic strategies targeting these pathways hold promise, this review emphasizes the challenges posed by context-dependent effects and intricate crosstalk within the cellular milieu. Insights into the molecular intricacies of these pathways offer a foundation for developing innovative therapeutic approaches, providing hope for enhanced cancer diagnostics and tailored treatment strategies.
Collapse
Affiliation(s)
- Muhanad Alhujaily
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha 61922, Saudi Arabia
| |
Collapse
|
2
|
Zhenhai Z, Qi C, Shuchao Z, Zhongqi W, Xue S, Zhijun G, Zhijie M, Jianmin L, Beibei L, Yuanyuan G. MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation. BMC Cancer 2023; 23:956. [PMID: 37814205 PMCID: PMC10563299 DOI: 10.1186/s12885-023-11175-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Accepted: 07/12/2023] [Indexed: 10/11/2023] Open
Abstract
MicroRNAs (miRNAs) have been reported to serve as potential biomarkers in bladder cancer and play important roles in cancer progression. This study aimed to investigate the biological role of miR-205-3p in bladder cancer. We showed that miR-205-3p was significantly down-regulated in bladder cancer tissues and cells. Moreover, overexpression of miR-205-3p inhibited bladder cancer progression in vitro. Then we confirmed that GLO1, a downstream target of miR-205-3p, mediated the effect of miR-205-3p on bladder cancer cells. In addition, we found that miR-205-3p inhibits P38/ERK activation through repressing GLO1. Eventually, we confirmed that miR-205-3p inhibits the occurrence and progress of bladder cancer by targeting GLO1 in vivo by nude mouse tumorigenesis and immunohistochemistry. In a word, miR-205-3p inhibits proliferation and metastasis of bladder cancer cells by activating the GLO1 mediated P38/ERK signaling pathway and that may be a potential therapeutic target for bladder cancer.
Collapse
Affiliation(s)
- Zou Zhenhai
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China
| | - Cheng Qi
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China
| | - Zhang Shuchao
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China
| | - Wang Zhongqi
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China
| | - Song Xue
- The Central Laboratory of the First Affiliated Hospital of Bengbu Medical College, Anhui, Bengbu, 233040, China
| | - Geng Zhijun
- The Central Laboratory of the First Affiliated Hospital of Bengbu Medical College, Anhui, Bengbu, 233040, China
| | - Mei Zhijie
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China
| | - Liu Jianmin
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China
| | - Liu Beibei
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China.
| | - Guo Yuanyuan
- Department of Urology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, 233040, Anhui, Bengbu, Longzihu, Bengbu, China.
| |
Collapse
|
3
|
Wang J, Yang X, Wang Z, Wang J. Role of the Glyoxalase System in Breast Cancer and Gynecological Cancer-Implications for Therapeutic Intervention: a Review. Front Oncol 2022; 12:857746. [PMID: 35898868 PMCID: PMC9309216 DOI: 10.3389/fonc.2022.857746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 06/17/2022] [Indexed: 12/24/2022] Open
Abstract
Methyglyoxal (MGO), an essential endogenous dicarbonyl metabolite, can lead to multiple physiological problems including hyperglycemia, kidney diseases, malignant tumors, beyond its normal concentration range. The glyoxalase system, making MGO maintained at a low level, links glycation to carcinogenesis, growth, metastasis, and cancer chemotherapy. The glyoxalase system comprises glyoxalase 1 (Glo1) and glyoxalase 2 (Glo2), which is often overexpressed in various tumor tissues. However, very little is known about the glyoxalase system in breast cancer and gynecological cancer. In this review, we introduce the role of the glyoxalase system in breast cancer, endometrial cancer, ovarian cancer and cervical cancer, and highlight the potential of the glyoxalase system to be both as a marker for diagnosis and a novel target for antitumor therapy. However, the intrinsic molecular biology and mechanisms of the glyoxalase system in breast cancer and gynecological cancer need further exploration.
Collapse
|
4
|
Rounds L, Nagle RB, Muranyi A, Jandova J, Gill S, Vela E, Wondrak GT. Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer. Cancers (Basel) 2021; 13:3608. [PMID: 34298821 PMCID: PMC8304603 DOI: 10.3390/cancers13143608] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 07/12/2021] [Accepted: 07/15/2021] [Indexed: 12/03/2022] Open
Abstract
Glyoxalase 1 (GLO1) is an enzyme involved in the detoxification of methylglyoxal (MG), a reactive oncometabolite formed in the context of energy metabolism as a result of high glycolytic flux. Prior clinical evidence has documented GLO1 upregulation in various tumor types including prostate cancer (PCa). However, GLO1 expression has not been explored in the context of PCa progression with a focus on high-grade prostatic intraepithelial neoplasia (HGPIN), a frequent precursor to invasive cancer. Here, we have evaluated GLO1 expression by immunohistochemistry in archival tumor samples from 187 PCa patients (stage 2 and 3). Immunohistochemical analysis revealed GLO1 upregulation during tumor progression, observable in HGPIN and PCa versus normal prostatic tissue. GLO1 upregulation was identified as a novel hallmark of HGPIN lesions, displaying the highest staining intensity in all clinical patient specimens. GLO1 expression correlated with intermediate-high risk Gleason grade but not with patient age, biochemical recurrence, or pathological stage. Our data identify upregulated GLO1 expression as a molecular hallmark of HGPIN lesions detectable by immunohistochemical analysis. Since current pathological assessment of HGPIN status solely depends on morphological features, GLO1 may serve as a novel diagnostic marker that identifies this precancerous lesion.
Collapse
Affiliation(s)
- Liliana Rounds
- Department of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA; (L.R.); (J.J.)
- Roche Diagnostics Solutions, Tucson, AZ 85755, USA; (A.M.); (S.G.); (E.V.)
| | - Ray B. Nagle
- Department of Pathology, University of Arizona, Tucson, AZ 85724, USA;
| | - Andrea Muranyi
- Roche Diagnostics Solutions, Tucson, AZ 85755, USA; (A.M.); (S.G.); (E.V.)
| | - Jana Jandova
- Department of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA; (L.R.); (J.J.)
| | - Scott Gill
- Roche Diagnostics Solutions, Tucson, AZ 85755, USA; (A.M.); (S.G.); (E.V.)
| | - Elizabeth Vela
- Roche Diagnostics Solutions, Tucson, AZ 85755, USA; (A.M.); (S.G.); (E.V.)
| | - Georg T. Wondrak
- Department of Pharmacology and Toxicology, College of Pharmacy & UA Cancer Center, University of Arizona, Tucson, AZ 85724, USA; (L.R.); (J.J.)
| |
Collapse
|